CNP analogue
Vosoritide
Answer
Vosoritide is authorised or registered in the US, the EU, Canada, Australia, Switzerland, Brazil and Turkey: 7 of the 10 registers read. Highest trial phase: Phase 3 (3 phase 3 trials, 0 with posted results). It has 23 registered trials, 12 of them running. Brand names on the FDA label register: Voxzogo 0.4mg.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
23 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 0 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 7 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Not on the register | MHRA, uk-mhra | 2026-09-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Not on the register | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Vosoritide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 23 trials
| NCT07441876 | Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia currently recruiting participants · register updated 2026-09-24 |
|---|---|
| NCT06668805 | A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment running, but no longer enrolling · register updated 2026-09-23 |
| 2024-512261-14-00 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in In no status recorded · register updated 2026-09-17 |
| NCT07073014 | Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia enrolling by invitation only · register updated 2026-09-09 |
| 2024-520137-74-00 | A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature no status recorded · register updated 2026-08-06 |
| 2024-517238-16-00 | A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondropla no status recorded · register updated 2026-07-03 |
| 2024-515861-33-00 | A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children with Noonan Syndrome with Inadequate Growth During or After H no status recorded · register updated 2026-06-24 |
| NCT06382155 | A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature currently recruiting participants · register updated 2026-05-22 |
| 2024-513129-22-00 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Ch no status recorded · register updated 2026-05-19 |
| 2025-523811-12-00 | A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide no status recorded · register updated 2026-05-05 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.